November 12, 2024--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing ...

Revenue Potential: Apitegromab has a total revenue potential of greater than $1 billion. Scholar Rock Holding Corp ...

Scholar Rock Holding ( (SRRK) ) has released its Q3 earnings. Here is a breakdown of the information Scholar Rock Holding presented to its ...

H.C. Wainwright raised the firm’s price target on Scholar Rock (SRRK) to $40 from $35 and keeps a Buy rating on the shares. Scholar Rock ...

Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) has been given a consensus rating of “Buy” by the seven brokerages ...

Good morning and welcome to Scholar Rock's Third Quarter 2024 Financial Results and Business Update Call. All participants will be in listen-only mode. After the company’s prepared remarks all ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Exhibit explores the many facets of modernist matriarch Gertrude Stein, who will be the subject of a conversation on Nov. 20 ...